Kardos Gregory R, Dai Mu-Shui, Robertson Gavin P
Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, USA; The Melanoma Center, The Pennsylvania State University College of Medicine, Hershey, PA, USA; The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Pigment Cell Melanoma Res. 2014 Sep;27(5):801-12. doi: 10.1111/pcmr.12259. Epub 2014 Jun 16.
Ribosome biogenesis can modulate protein synthesis, a process heavily relied upon for cancer cell proliferation. In this study, involvement of large subunit ribosomal proteins (RPLs) in melanoma has been dissected and RPLs categorized based on modulation of cell proliferation and therapeutic targeting potential. Based on these results, two categories of RPLs were identified: the first causing negligible effects on cell viability, p53 expression, and protein translation, while the second category decreased cell viability and inhibited protein synthesis mediated with or without p53 protein stabilization. RPL13 represents the second category, where siRNA-mediated targeting inhibited tumor development through decreased cellular proliferation. Mechanistically, decreased RPL13 levels increased p53 stability mediated by RPL5 and RPL11 binding to and preventing MDM2 from targeting p53 for degradation. The consequence was p53-dependent cell cycle arrest and decreased protein translation. Thus, targeting certain category 2 RPL proteins can inhibit melanoma tumor development mediated through the MDM2-p53 pathway.
核糖体生物合成可以调节蛋白质合成,而蛋白质合成是癌细胞增殖所高度依赖的过程。在本研究中,已剖析了大亚基核糖体蛋白(RPLs)在黑色素瘤中的作用,并根据对细胞增殖的调节和治疗靶向潜力对RPLs进行了分类。基于这些结果,确定了两类RPLs:第一类对细胞活力、p53表达和蛋白质翻译的影响可忽略不计,而第二类则降低细胞活力并抑制有或无p53蛋白稳定介导的蛋白质合成。RPL13属于第二类,其中小干扰RNA(siRNA)介导的靶向作用通过降低细胞增殖来抑制肿瘤发展。从机制上讲,RPL13水平降低会增加由RPL5和RPL11与MDM2结合并阻止MDM2将p53靶向降解所介导的p53稳定性。其结果是p53依赖性细胞周期停滞和蛋白质翻译减少。因此,靶向某些2类RPL蛋白可以抑制通过MDM2-p53途径介导的黑色素瘤肿瘤发展。